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Evidence from natural history
During the natural history of chronic hepatitis B virus (HBV)
infection, the loss of serum hepatitis B e antigen (HBeAg)
and the development of anti-HBe antibodies (HBeAg sero-
conversion) make a transition from the immune-clearance
phase of disease to the inactive carrier state. Clinical
studies on the natural history involving patients with
HBeAg-positive chronic hepatitis B (CHB) have demon-
strated that HBeAg seroconversion confers improved out-
comes, including a sustained reduction in HBV DNA levels, a
regression of fibrosis, a lower risk for cirrhosis and hepa-
tocellular carcinoma and a higher incidence of
complication-free survival [1e3]. Hsu et al reported on the
natural course of chronic HBV infection after spontaneous
HBeAg seroconversion in 283 patients [2]; the estimated
annual incidence of cirrhosis and hepatocellular carcinoma
development was 0.9% and 0.2%, respectively, during a
mean follow-up of 8.6 years. Another study involving pa-
tients with perinatally acquired chronic HBV infection has
shown that spontaneous HBeAg seroconversion occurring at
age 15e35 years is associated with a low rate of progression
to cirrhosis, whereas delayed seroconversion (after age 40
years ) confers a poorer prognosis [4]. Thus, the younger
the age at which HBeAg seroconversion occurs, the better
the outcome.
Evidence from antiviral therapy
A finite course of pegylated interferon (PegIFN) therapy is
associated with higher HBeAg seroconversion rates at the
end of treatment compared with 1 year of oral nucleoside/
nucleotide analogue (NA) therapy (w27% of PegIFN vs.
w21% of NA) [5,6]. The HBeAg seroconversion rate
increased to 33% and to 48% when assessed at 6 months and
12 months, respectively, after the end of PegIFN treatmenthttp://dx.doi.org/10.1016/j.aidm.2014.07.001
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Elsevier Taiwan LLC. Open access under CC BY-NC-ND license.[5,7]. By contrast, HBeAg seroconversion is usually not du-
rable after 1 year of lamivudine therapy [8]. The lack of
durability may result from the failure of lamivudine to
completely suppress viral replication and the selection of
drug-resistant viral mutants. Our study has demonstrated
that HBV genotype B infection, younger (age < 36 years)
and consolidation therapy (additional 6e12 months’ treat-
ment) after HBeAg seroconversion can improve the post
lamivudine treatment durability [9]. The newer oral NAs
such as entecavir or tenofovir have shown greater efficacy
in profoundly lowering HBV DNA levels, but this enhanced
efficacy has not been associated with a concomitant in-
crease in HBeAg seroconversion rate after 1 year of therapy
[10]. Data from long-term follow-up studies of continuous
oral NA treatment showed that HBeAg seroconversion
increased over time [10]. Treatment-induced HBeAg sero-
conversion has also been shown to confer favorable out-
comes and is a strong predictor of prolonged survival
between Caucasian and Asian patients [11]. It is now
evident that HBeAg seroconversion in associated with po-
lymerase chain reaction-undetectable serum HBV DNA
levels is an achievable goal with oral NA treatment and can
provide the possibility of improved outcomes with a finite
course of therapy for individuals with HBeAg-positive CHB.
Thus, a finite course of NA therapy may induce sustained
HBeAg seroconversion and provide full immunologic control
of disease in patients who would otherwise experience
delayed seroconversion, high viral load, and increased risk
for the progression of liver disease.
Strategy to maximize HBeAg seroconversion
during a finite therapeutic course
The guideline of the CHB reimbursement policy of the Na-
tional Health Insurance administration in Taiwan demon-
strated that the therapeutic period of NA in treating HBeAg-
positive patients is 3 years. If patients achieved HBeAg loss
during NA treatment, they could take NA for an additional
one year of therapy as the consolidation phase. Clearly, thean and The Digestive Endoscopy Society of Taiwan. Published by
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patients at the right time to maximize the possibility of
HBeAg loss or seroconversion within the 3-year therapeutic
period. Hence, based on personal pretreatment charac-
teristics and on-treatment virological response during NA
therapy are crucial for patients to achieve HBeAg sero-
conversion within a finite period. This is called personalized
therapy. In this issue of Advances in Digestive Medicine, Su
et al [12] reported a multicenter study concerning the ef-
ficacy of entecavir therapy in HBeAg-positive patients in
Taiwan. They treated 132 HBeAg-positive naı¨ve patients
with oral entecavir 0.5 mg daily. The 2-year cumulative
HBeAg loss rate was 33.3%. Multivariate analysis after
adjustment for age, gender, and alanine aminotransferase
(ALT), they found younger age and female gender were two
independent predictors to HBeAg loss. Furthermore, the
HBeAg loss rate at 2 years was 46% in younger patients and
increased up to 73% in young female patients. Recently,
Chan et al [13] reported the effects of tenofovir disoproxil
fumarate in HBeAg-positive patients within immune toler-
ance phase. They also found that female gender was an
independent baseline factors to predict the serum HBV DNA
undetectable at 192 weeks. In addition, our earlier study
[14] found increased pretreatment ALT levels and lower
HBV DNA could predict a higher probability of HBeAg loss
after 1 year of treatment with lamivudine. Zeuzem et al
[15] found that the early on-treatment response by non-
detectable serum HBV DNA at treatment week 24 is the
strongest predictor for optimal outcomes (HBeAg serocon-
version, 52%; drug resistance, 1.8%) at 2 years during tel-
bivudine therapy . Obviously, the baseline characteristics
and early on-treatment responses are useful in maximizing
the possibility of HBeAg loss or seroconversion during NA
treatment. Physicians should be aware of the baseline
features of serum HBV DNA, ALT, age, gender, and HBV
genotype prior to NA treatment and do on-treatment
monitoring of serum HBV DNA at 24 weeks during NA
treatment to maximize the possibility of HBeAg loss or
seroconversion and to accomplish the personalized therapy
of patients with CHB.
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